The Philippines has taken a significant step in enhancing its national immunization program by evaluating the cost-effectiveness of two 10-valent pneumococcal conjugate vaccines. This move aims to reduce the burden of invasive pneumococcal diseases such as pneumonia, meningitis, and bacteraemia among the population.
Evaluating Cost-Effectiveness
Researchers adapted an existing Markov model to the Philippine healthcare context, assessing health outcomes over a five-year horizon. The study compared the 10-valent PCV10-SII and the 10-valent PHiD-CV vaccines against a scenario with no vaccination. Quality-adjusted life years (QALYs) and associated costs were projected over a lifetime, factoring in a discount rate of 3.66%. The PCV10-SII was priced 20% below the market rate of PHiD-CV, with variations considered in different scenarios.
Health Benefits and Economic Impact
Both vaccination strategies demonstrated superiority over no vaccination, delivering enhanced health benefits while reducing total costs. Specifically, PHiD-CV was associated with a higher number of QALYs gained, primarily by preventing more cases of meningitis, bacteraemia, and acute otitis media. However, this came at a higher direct cost compared to PCV10-SII.
– Implementing PCV10-SII could offer significant cost savings if the price remains competitive.
– PHiD-CV’s higher efficacy in preventing certain diseases translates to better overall health outcomes.
– The cost-effectiveness of vaccines is highly sensitive to price variations, influencing decision-making in national health policies.
The analysis indicates that the PHiD-CV becomes the preferred option if the price reduction for PCV10-SII does not exceed 5%, highlighting the critical role of vaccine pricing in public health strategies.
Adopting either vaccination strategy will undoubtedly lead to better health outcomes and economic savings for the Philippines. However, the choice between PCV10-SII and PHiD-CV hinges on the balance between cost and the extent of disease prevention required. Policymakers must consider these factors carefully to optimize the health benefits within budget constraints.
Ensuring access to effective and affordable vaccines is paramount for reducing the incidence of severe pneumococcal diseases. The study underscores the importance of negotiating vaccine prices and selecting the most economically viable options to maximize public health benefits. Moving forward, continuous evaluation of vaccine performance and costs will be essential in sustaining the success of the national immunization program.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
